The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.
Also called NCT02982434
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 180 participants
- Registry
-
NCT02982434
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Unknown status
Technical summary
Registry record NCT02982434. Randomized; double masking; primary purpose treatment. Start 2016-09 (registry gives no type); primary completion 2017-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
- Condition
- Atrial Fibrillation
- Condition
- Ischemic Heart Disease
- Intervention (Drug)
- Pharmaceutical composition containing botulinum toxin
- Intervention (Drug)
- 0.9% normal saline
- Intervention (Procedure)
- Coronary artery bypass grafting
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
Record details
- Record id
cardio:ct-nct02982434- Content hash
cc10a7b0223f577c5fc2ebb394f4fefcbe7e64a7833422abbfea59f7a364fa83